![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
(MM) | NASDAQ:DARA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.88 | 0 | 01:00:00 |
WILMINGTON, Del., June 10, 2015 /PRNewswire/ -- Rigrodsky & Long, P.A.:
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of DARA BioSciences, Inc. ("DARA" or the "Company") (NASDAQ CM: DARA) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by Midatech Pharma PLC ("Midatech").
Click here to learn more: http://rigrodskylong.com/investigations/dara-biosciences-inc-dara.
Under the terms of the agreement, shareholders of DARA will receive (i) 0.272 Ordinary Shares of Midatech, subject to certain adjustments described in more detail below, and (ii) one Contingent Value Right ("CVR"). All Midatech Ordinary Shares will be delivered to the holders of DARA Common Stock in the form of American Depositary Receipts ("ADRs"). Based on the current price of Midatech, each DARA share will be converted into ADRs with a value equivalent to approximately $1.20 per DARA share. The ADRs will be listed on NASDAQ. Current DARA stockholders are expected to own approximately 16% of Midatech after the closing of the transaction.
The investigation concerns whether DARA's board of directors failed to adequately shop the Company and obtain the best possible value for DARA's shareholders before entering into an agreement with Midatech.
If you own the common stock of DARA and purchased your shares before June 4, 2015, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com, or at: http://rigrodskylong.com/investigations/dara-biosciences-inc-dara.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT:
Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com
http://www.rigrodskylong.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dara-biosciences-inc-shareholder-alert-rigrodsky--long-pa-announces-investigation-of-buyout-300097140.html
SOURCE Rigrodsky & Long, P.A.
Copyright 2015 PR Newswire
1 Year (MM) Chart |
1 Month (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions